C. Catania

G. Pelosi, F. D. De Braud, G. Curigliano, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated NSCLC: a meta-analysis of randomized clinical trials.

P. Queirolo, V. Bagnardi, P. Tarantino, 2020 .

Real Time Quantitative PCR Publications

L. Spaggiari, L. Luzi, L. Bernard, 2014 .

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review

F. de Marinis, G. Viale, G. Curigliano, 2021, Current oncology.

Gemcitabine-induced systemic capillary leak syndrome.

L. Spaggiari, G. Curigliano, F. de Braud, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

G. Giaccone, P. Queirolo, V. Bagnardi, 2021, ESMO open.

Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.

C. Greco, S. Ramella, A. Filippi, 2022, Critical reviews in oncology/hematology.

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

F. de Marinis, A. Passaro, G. Antonarelli, 2022, Frontiers in Oncology.

Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma.

A. Goldhirsch, F. D. De Braud, M. Aapro, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Opinions concerning euthanasia, life-sustaining treatment and acceleration of death: results of an Italian Association of Medical Oncology (AIOM) survey.

D. Radice, F. Boccardo, O. Bertetto, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.

G. Giaccone, A. Santoro, V. Bagnardi, 2022, The Lancet. Oncology.

Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy.

B. Bonanni, G. Curigliano, F. Conforti, 2021, European journal of cancer.

Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.

C. Boni, G. Curigliano, O. Pagani, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-ﬁnding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer

G. Blanchot, A. Goldhirsch, G. Sanna, 2006 .

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

F. de Marinis, G. Curigliano, C. Santoro, 2022, Clinical Lung Cancer.

Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature.

G. Curigliano, P. Queirolo, P. Tarantino, 2020, Cancer treatment reviews.

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.

G. Curigliano, P. Queirolo, P. Ferrucci, 2022, European journal of cancer.

Breast cancer and pregnancy: how safe is trastuzumab?

A. Goldhirsch, H. Azim, F. Peccatori, 2009, Nature Reviews Clinical Oncology.

A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.

L. Spaggiari, F. D. De Braud, G. Curigliano, 2006, Lung cancer.

High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study.

G. Curigliano, Z. Ballatore, R. Berardi, 2023, Lung cancer.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

A. Delmonte, M. Santarpia, M. Barberis, 2014, Critical reviews in oncology/hematology.

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

P. Solli, G. Veronesi, L. Spaggiari, 2012, Critical reviews in oncology/hematology.

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

F. de Marinis, S. Gandini, F. Bertolini, 2019, Clinical and Translational Oncology.

The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.

N. Pennell, G. Spitaleri, C. Catania, 2021, Clinical Lung Cancer.

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion

G. Giaccone, R. Gelber, C. Swanton, 2021, Clinical Cancer Research.

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

F. de Marinis, L. Preda, M. Barberis, 2014, OncoTargets and therapy.

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.

G. Curigliano, G. Lo Russo, P. Zucali, 2022, European journal of cancer.

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

F. de Marinis, A. Rappa, M. Barberis, 2017, Pharmacological research.

Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer

E. Giovannetti, D. Radice, G. Pelosi, 2010, The Pharmacogenomics Journal.

Afatinib in NSCLC harbouring EGFR mutations.

F. de Marinis, A. Passaro, C. Catania, 2014, The Lancet. Oncology.

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

L. Spaggiari, F. D. De Braud, A. Delmonte, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

F. Conforti, L. Pala, C. Catania, 2017, Future oncology.

Clinical and pathological response to pre-operative crizotinib in a patient with ALK-translocated NSCLC

F. Petrella, P. Solli, G. Perrone, 2016 .

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

C. Specchia, F. de Marinis, P. Queirolo, 2020, JNCI cancer spectrum.

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

F. de Marinis, M. Barberis, C. Fumagalli, 2015, OncoTargets and therapy.

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

R. Gelber, M. Piccart, P. Arnone, 2023, Breast.

Participation in Clinical Trials as Viewed by the Patient: Understanding Cultural and Emotional Aspects Which Influence Choice

D. Radice, A. Goldhirsch, F. D. De Braud, 2008, Oncology.

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

A. Hauschild, J. Becker, P. Ascierto, 2019, Cancer Immunology, Immunotherapy.

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients

F. de Marinis, G. Viale, M. Barberis, 2019, Journal of clinical medicine.

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.

A. Delmonte, M. Santarpia, M. Duca, 2013, Lung cancer.

Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors

F. de Marinis, M. Barberis, F. Conforti, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

F. de Marinis, R. Rosell, N. Karachaliou, 2016, OncoTargets and therapy.

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data

F. de Marinis, C. Noberasco, A. Passaro, 2016, Expert review of clinical pharmacology.

Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

F. de Marinis, C. Noberasco, A. Passaro, 2016, Journal of Thoracic Disease.

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

R. Labianca, L. Spaggiari, M. Giovannini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, F. D. De Braud, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, C. Bordignon, 2011 .

Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.

A. Luini, A. Goldhirsch, G. Viale, 2013, Critical reviews in oncology/hematology.

Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study.

Robin L. Jones, J. Blay, M. Toulmonde, 2022, European journal of cancer.

Brain metastases in patients with advanced breast cancer.

A. Goldhirsch, M. Médici, E. Botteri, 2007, Anticancer research.

Sex and cancer immunotherapy: Current understanding and challenges.

G. Giaccone, R. Gelber, S. Minucci, 2022, Cancer cell.

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey

D. Radice, F. de Marinis, L. Gianoncelli, 2020, Frontiers in Oncology.

Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.

G. Giaccone, L. Spaggiari, J. Vansteenkiste, 2019, European journal of cancer.

“Waiting and the Waiting Room: How Do You Experience Them?” Emotional Implications and Suggestions from Patients with Cancer

Davide Radice, D. Radice, A. Goldhirsch, 2011, Journal of Cancer Education.

“Care and self-care” “god as a mirror of the self”

V. Zagonel, C. Catania, Italian Society of Medical Oncology Working Group “Humaniz Organization”, 2009, Journal of Cancer Education.

Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis

D. Radice, F. de Marinis, L. Gianoncelli, 2020, AntiCancer Research.

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

F. Conforti, L. Pala, D. Laszlo, 2023, Current oncology.

Journey of Hope.

C. Catania, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model

L. Spaggiari, F. de Marinis, L. Gianoncelli, 2020, Frontiers in Oncology.

Perception that Oral Anticancer Treatments are Less Efficacious: Development of a Questionnaire to Assess the Possible Prejudices of Patients with Cancer

L. Mariani, A. Goldhirsch, A. Rocca, 2005, Breast Cancer Research and Treatment.

Safety of systemic chemotherapy in a patient with mitochondrial myopathy and non-small-cell lung cancer.

N. Bresolin, G. Comi, A. Delmonte, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide in the elderly: clinical considerations for a better drug management.

F. D. De Braud, G. Curigliano, A. Comandone, 2000, Critical reviews in oncology/hematology.

Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).

A. Goldhirsch, U. Veronesi, G. Martinelli, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

F. D. De Braud, G. Curigliano, A. Gambino, 2008, Ecancermedicalscience.

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study

D. Radice, A. Goldhirsch, A. Delmonte, 2014, Psycho-oncology.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

E. Giovannetti, N. Funel, G. Peters, 2018, Oncotarget.

Humanism in Oncology "Care and Self-Care" "God as a Mirror of the Self" CHIARA CATANIA, MD, VITTORINA ZAGONEL, MD, ON BEHALF OF ITALIAN SOCIETY OF MEDICAL ONCOLOGY (AIOM) WORKING GROUP: "HUMANIZATION AND ORGANIZATION"

C. Catania, 2009 .

Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.

A. Goldhirsch, M. Mandalà, M. Zampino, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach

Francesca Russo, Giuseppe Pelosi, Davide Radice, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.

L. Spaggiari, F. D. De Braud, C. Noberasco, 2009, Annals of Oncology.

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre

A. Goldhirsch, M. Médici, G. Sanna, 2007, Breast Cancer Research and Treatment.

Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making.

F. de Marinis, M. Barberis, A. Passaro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The Desire for Life and Motherhood Despite Metastatic Lung Cancer.

G. Spitaleri, C. Catania, E. del Signore, 2019, JAMA oncology.

Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination.

D. Radice, A. Goldhirsch, M. Médici, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Solitude and fear during the great coronavirus war

L. Gianoncelli, C. Catania, Ester Del Signore, 2020 .

New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP.

C. Bennati, C. Greco, E. Olmetto, 2023, Critical reviews in oncology/hematology.

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

M. Zucchetti, F. D. De Braud, A. Delmonte, 2014, The Oncologist.

Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors.

R. Berardi, S. Cascinu, D. Neri, 2010 .

Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.

G. Giaccone, P. Queirolo, P. Zucali, 2020 .

Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials.

S. Cascinu, P. Conte, D. Neri, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

F. de Marinis, M. Barberis, C. Fumagalli, 2015, OncoTargets and therapy.

Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.

R. Gelber, S. Minucci, V. Bagnardi, 2023, Seminars in oncology.

Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?

A. Goldhirsch, G. Curigliano, M. Colleoni, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.